Manager of the Year 2012 is Vojmir Urlep, President of the Board of Management of Lek, a Sandoz company
The management board of the Managers Association selected Vojmir Urlep, President of the Board of Management of Lek, a Sandoz company, as Manager of the Year 2012. Recognition will be awarded to him at the Management Congress on Thursday, 27 September, in Portorož.
According to the opinion of the management board of the Managers Association, Lek, a Sandoz company, under the direction of Vojmir Urlep delivers above-average business results, above-average customer and employee satisfaction, high added value, and plays a leading role within the Sandoz Group. All these are excellent prospects for further global development of the oldest Slovenian pharmaceutical company.
From Lek he created the largest Sandoz development center
Vojmir Urlep, a double master degree holder– in pharmacy and economics, was first employed in Lek back in 1983. Throughout the following fifteen years he was leading the sales across the African region, led the representative office in Moscow, Lek Zagreb Company, in the period 1996-1998 he was a member of the Lek board of management and president of the Lek board of management. He left the company for seven years to take over the running of Kemofarmacija company, but returned in 2007 as president of the board of Lek management and currently also performs the function of Head of Novartis in Slovenia.
In the recent period of his leadership, Lek with its seven production sites and three development centers for difficult-to-make products (active pharmaceutical ingredients, final dosage forms and biosimilars) has become the largest Sandoz’ development center. In 2011, Lek’s products accounted for one quarter of all development projects and the most important products launched by Sandoz, which is the largest volume within this generic group. Filing on average 20 patent applications every year and having over 1,200 patent rights obtained around the world, Lek has made a significant contribution to Sandoz’ sales which increased by ten per cent last year.
With outstanding results and high investment in development
After 2008, Lek has transformed itself predominantly into a global development and production center for difficult-to-make technologies, and the majority of the sales take place within Sandoz Group on the principle of internal pricing. Lek shows excellent business results:
- 641.8 million EUR revenue, a 9% increase versus year 2010,
- 117 million EUR EBITDA,
- 73.8 million EUR net income (net income in 2010 was 47.9 million EUR),
- added value per employee equals 95,226 EUR (which represents a 5% increase versus 2010),
- 8-10% of revenue invested in research and development,
- with 2,987 EUR, the average gross earnings are double the Slovenian average,
- return on equity exceeds 12%, positioning Lek as a top performer within Sandoz network.
Transformation of Lek with a clear focus on development and production coincides with Vojmir Urlep taking up the position as the head of the company. In the period since he become a president of the board of management, the production volume in key areas has increased by 150 to more than 300 per cent, there has also been a growth in the number of development projects, especially in the proportion of technologically most demanding ones. Lek has gradually adapted to a different role within the international group and has been establishing an inclusive organisational culture. As a result of investments of 1.1 billion EUR since 2002, Lek is, with regard to technological equipment, one of the world leaders in the pharmaceutical industry. Lek is also present in currently most demanding field of development and production of biosimilars. This positions Lek, a Sabdoz company, among the few rare companies worldwide with knowledge and expertise in this area.
Lek associates occupy also prominent positions within Sandoz Group
Lek actively recruits, predominantly highly qualified staff, which now account for 40% of 2,571 employees. There is considerable mobility of staff and many Lek associates have already taken up some of leading roles at Sandoz.
At Lek, the greatest credit for realisation of Lek’s vision to ´Become the leading Sandoz development and production center for difficult-to-make products´ is attributed to president of the board of management, who is also valued as a personal coach by many associates. Vojmir Urlep does not create an atmosphere of excellence and dedication only at Lek but for 16 years also as a lecturer on marketing at the Pharmacy faculty at the University of Ljubljana. Vojmir Urlep is active on many boards, such as the Pension Company A supervisory board, supervisory board of the Slovenian Chamber of Commerce and the strategic council for internationalisation at the Slovenian Chamber of Commerce.
All these achievements are a reason for which the management board of the Manager Association presents the Manager of the Year 2012 award to president of the Lek board of management, Vojmir Urlep.
About Manager of the Year Award
The members of the commission for selecting the Manager of the Year are: Tomaž Berločnik (chair), Franjo Bobinac, Jože Colarič, Tatjana Fink, Sonja Gole, Sebastijan Piskar, Sonja Šmuc and Dejan Turk. The Manager of the Year 2012 will be traditionally presented at the Management Congress on 27 September in GH Bernardin in Portorož. Last year’s winner of the award was Christof Droste, managing director of Hella Saturnus.
More about the reward and recent recipients on www.zdruzenje-manager.si
Additional information on the congress and accreditations:
Edita Krajnović │040 488 040 │ email@example.com
Lek, a Sandoz company, is one of the pillars of leading world generics company Sandoz. Its role within Sandoz is to act as: a global development center for products and technologies; a global manufacturing center for active pharmaceutical ingredients and medicines; a competence center for the development of vertically integrated products; a Sandoz competence center in the field of development and manufacturing of biosimilar products; and, a supply center for the markets of Central and Eastern Europe (CEE), South East Europe (SEE) and Commonwealth of Independent States (CIS), and it is responsible for sales on the Slovenian market. For further information please visit http://www.lek.si/eng/.
Sandoz, a Division of the Novartis group, is a global leader in the field of generic pharmaceuticals, offering a wide array of high-quality, affordable products that are no longer protected by valid and enforceable third-party patents. Sandoz has a portfolio of approximately 1000 compounds and sells its products in about 130 countries. Key product groups include cardiovascular medicines, anti-infectives, treatments for central nervous system and alimentary tract disorders, oncology and respiratory therapies, as well as medications for blood and blood forming organ disorders. Sandoz develops, produces and markets these medicines along with pharmaceutical and biotechnological active substances. In addition to strong organic growth in recent years, Sandoz has made a series of acquisitions including Lek (Slovenia), Sabex (Canada), Hexal (Germany), Eon Labs (US), EBEWE Pharma (Austria), and Oriel Therapeutics (US). In 2011, Sandoz employed more than 24,000 people (full-time equivalents) worldwide and achieved net sales of USD 9.5 billion for the full year. For more information, please visit www.sandoz.com.
Sandoz is on Twitter. Sign up to follow @Sandoz_global at http://twitter.com/sandoz.
Novartis provides innovative healthcare solutions that address the evolving needs of patients and societies. Headquartered in Basel, Switzerland, Novartis offers a diversified portfolio to best meet these needs: innovative medicines, eye care, cost-saving generic pharmaceuticals, preventive vaccines and diagnostic tools, over-the-counter and animal health products. Novartis is the only global company with leading positions in these areas. In 2011, the Group’s continuing operations achieved net sales of USD 58.6 billion, while approximately USD 9.6 billion (USD 9.2 billion excluding impairment and amortization charges) was invested in R&D throughout the Group. Novartis Group companies employ approximately 124,000 full-time-equivalent associates and operate in more than 140 countries around the world. For more information, please visit www.novartis.com.
Novartis is on Twitter. Sign up to follow @Novartis at http://twitter.com/novartis.
This press release contains statements and conclusions based on projections of Lek’s future business operations. These estimates are derived from the best information currently available. In case these forecasts prove unreliable, the actual results could prove different from those projected.
For additional information contact:
Lek Pharmaceuticals d. d.
Phone: +386 1 580 22 43
Fax: +386 1 580 24 32